Eli Lilly (LLY) announced on Thursday the launch of the Employer Connect platform, which enables employees to access its obesity therapy Zepbound at a lower cost through a network of pharmacies and a group of program administrators.
Employers participating in the platform will connect with more than fifteen independent program administrators, including Teladoc (TDOC), GoodRx (GDRX), and a network of dispensing pharmacies such as HealthDyne and CenterWell.
Through this platform, the Indiana-based drugmaker plans to sell its popular GLP-1 medicine, Zepbound, in a single-patient delivery device called KwikPen to network pharmacies at a discounted price of $449 for all doses.
The choice of pharmacy and program administrator will determine the final cost to employers, and out-of-pocket expenses to employees will differ depending on dispensing and service fees charged by program administrators and employers’ cost-share model.
“By enabling coverage outside traditional benefit designs, we lower barriers to treatment and give employers greater control over how they support employee access to obesity care,” said Kevin Hern, Senior Vice President, Lilly Employer.